Magnetic Resonance Imaging and Spectroscopy of the Prostate

Completed

• Conditions: Prostate Cancer

• Registration Number: NCT00590993
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

Past studies have shown that MRI is useful for staging prostate cancer. This study will use magnetic resonance spectroscopic imaging (MRSI) to obtain more information. MRSIs with MRIs help doctors locate prostate cancer and determine the extent of tumor before deciding on treatment. This study looks at structural and chemical properties of prostates in prostate cancer patients before and after treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2000-12
• Study First Submitted: 2007-12-26
• Study First Submitted QC: 2007-12-26
• Study First Posted: 2008-01-11
• Primary Completion: 2013-02
• Study Completion: 2013-02
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-23
• Last Update Posted: 2023-10-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 1005

Inclusion Criteria

• prostate cancer patients willing to undergo a MRI and MRSI exam

Exclusion Criteria

• patients with prostate cancer and bone or lymph node metastasis
• patients who can not have an MRI exam

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determine added value in combining MRSI and MRI in prostate cancer treatment	3 hours

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States